Preclinical FLT-PET and FDG-PET imaging of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901

Lee, 2009, Epothilones: tubulin polymerization as a novel target for prostate cancer therapy, Nat Clin Pract Oncol, 6, 85, 10.1038/ncponc1281 Janssen, 2011, Mitosis as an anti-cancer target, Oncogene, 30, 2799, 10.1038/onc.2011.30 Teicher, 2008, Newer cytotoxic agents: attacking cancer broadly, Clin Cancer Res, 14, 1610, 10.1158/1078-0432.CCR-07-2249 Warner, 2008, Tubulin-associated proteins: Aurora and Polo-like kinases as therapeutic targets in cancer, Curr Oncol Rep, 10, 122, 10.1007/s11912-008-0020-0 Gautschi, 2008, Aurora kinases as anticancer drug targets, Clin Cancer Res, 14, 1639, 10.1158/1078-0432.CCR-07-2179 Ruchaud, 2007, Chromosomal passengers: conducting cell division, Nat Rev Mol Cell Biol, 8, 798, 10.1038/nrm2257 Keen, 2004, Aurora-kinase inhibitors as anticancer agents, Nat Rev Cancer, 4, 927, 10.1038/nrc1502 Girdler, 2006, Validating Aurora B as an anti-cancer drug target, J Cell Sci, 119, 3664, 10.1242/jcs.03145 Carvajal, 2006, Aurora kinases: new targets for cancer therapy, Clin Cancer Res, 12, 6869, 10.1158/1078-0432.CCR-06-1405 Dees, 2012, Phase 1 Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations, Clin Cancer Res, 18, 4775, 10.1158/1078-0432.CCR-12-0589 Cervantes, 2012, Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors, Clin Cancer Res, 18, 4764, 10.1158/1078-0432.CCR-12-0571 Farrell, 2013, Biological Characterization of TAK-901, an Investigational, Novel, Multi-Targeted Aurora B Kinase Inhibitor, Mol Cancer Ther, 12, 460, 10.1158/1535-7163.MCT-12-0657 Stroobants, 2003, 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec), Eur J Cancer, 39, 2012, 10.1016/S0959-8049(03)00073-X Bollag, 2010, Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma, Nature, 467, 596, 10.1038/nature09454 Takeuchi, 2011, 18F-fluorothymidine PET/CT as an early predictor of tumor response to treatment with cetuximab in human lung cancer xenografts, Oncol Rep, 26, 725 Ullrich, 2008, Early detection of erlotinib treatment response in NSCLC by 3′-deoxy-3′-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET), PLoS One, 3, e3908, 10.1371/journal.pone.0003908 Mileshkin, 2011, Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib, Clin Cancer Res, 17, 3304, 10.1158/1078-0432.CCR-10-2763 Chan, 2007, Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity, Mol Cancer Ther, 6, 3147, 10.1158/1535-7163.MCT-07-2156 Dorow, 2006, Multi-tracer small animal PET imaging of the tumor response to the novel pan-Erb-B inhibitor CI-1033, Eur J Nucl Med Mol Imaging, 33, 441, 10.1007/s00259-005-0039-5 Kim, 2011, Down-regulation of Aurora B kinase induces cellular senescence in human fibroblasts and endothelial cells through a p53-dependent pathway, FEBS Lett, 585, 3569, 10.1016/j.febslet.2011.10.022 Huck, 2010, MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo, Mol Cancer Res, 8, 373, 10.1158/1541-7786.MCR-09-0300 Moroz, 2011, Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3′-deoxy-3′-[18F]fluorothymidine imaging, Clin Cancer Res, 17, 1099, 10.1158/1078-0432.CCR-10-1430 Manfredi, 2011, Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays, Clin Cancer Res, 17, 7614, 10.1158/1078-0432.CCR-11-1536 Cass, 1979, Fluctuations in nucleoside uptake and binding of the inhibitor of nucleoside transport, nitrobenzylthioinosine, during the replication cycle of HeLa cells, Cancer Res, 39, 1245 Pressacco, 1995, Modulation of the equilibrative nucleoside transporter by inhibitors of DNA synthesis, Br J Cancer, 72, 939, 10.1038/bjc.1995.437 Ritzel, 2001, Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib), J Biol Chem, 276, 2914, 10.1074/jbc.M007746200 Paproski, 2010, Biodistribution and uptake of 3′-deoxy-3′-fluorothymidine in ENT1-knockout mice and in an ENT1-knockdown tumor model, J Nucl Med, 51, 1447, 10.2967/jnumed.110.076356 Sun, 2011, 18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy, J Nucl Med, 52, 140, 10.2967/jnumed.110.080606 Mudd, 2012, Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft model, Mol Imaging Biol, 14, 617, 10.1007/s11307-011-0529-8